title: Expression and role of RIP140/NRIP1 in chronic lymphocytic leukemia.
abstract: RIP140 is a transcriptional coregulator, (also known as NRIP1), which finely tunes the activity of various transcription factors and plays very important physiological roles. Noticeably, the RIP140 gene has been implicated in the control of energy expenditure, behavior, cognition, mammary gland development and intestinal homeostasis. RIP140 is also involved in the regulation of various oncogenic signaling pathways and participates in the development and progression of solid tumors. During the past years, several papers have reported evidences linking RIP140 to hematologic malignancies. Among them, two recent studies with correlative data suggested that gene expression signatures including RIP140 can predict survival in chronic lymphocytic leukemia (CLL). This review aims to summarize the literature dealing with the expression of RIP140 in CLL and to explore the potential impact of this factor on transcription pathways which play key roles in this pathology.
authors: IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, France. marion.lapierre@inserm.fr.|INSERM, U1194, Montpellier, F-34298, France. marion.lapierre@inserm.fr.|Université de Montpellier, Montpellier, F-34298, France. marion.lapierre@inserm.fr.|Institut régional du Cancer de Montpellier, Montpellier, F-34298, France. marion.lapierre@inserm.fr.
authors: Marion
authors: M
authors: Lapierre
authors: IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, France. audrey-castet@chu-montpellier.fr.|INSERM, U1194, Montpellier, F-34298, France. audrey-castet@chu-montpellier.fr.|Université de Montpellier, Montpellier, F-34298, France. audrey-castet@chu-montpellier.fr.|Institut régional du Cancer de Montpellier, Montpellier, F-34298, France. audrey-castet@chu-montpellier.fr.|Pharmacie, CHU Montpellier, Montpellier, F-34298, France. audrey-castet@chu-montpellier.fr.
authors: Audrey
authors: A
authors: Castet-Nicolas
authors: IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, France. delphine.gitenay@inserm.fr.|INSERM, U1194, Montpellier, F-34298, France. delphine.gitenay@inserm.fr.|Université de Montpellier, Montpellier, F-34298, France. delphine.gitenay@inserm.fr.|Institut régional du Cancer de Montpellier, Montpellier, F-34298, France. delphine.gitenay@inserm.fr.
authors: Delphine
authors: D
authors: Gitenay
authors: IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, France. stephan.jalaguier@inserm.fr.|INSERM, U1194, Montpellier, F-34298, France. stephan.jalaguier@inserm.fr.|Université de Montpellier, Montpellier, F-34298, France. stephan.jalaguier@inserm.fr.|Institut régional du Cancer de Montpellier, Montpellier, F-34298, France. stephan.jalaguier@inserm.fr.
authors: Stéphan
authors: S
authors: Jalaguier
authors: IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, France. catherine.teyssier@inserm.fr.|INSERM, U1194, Montpellier, F-34298, France. catherine.teyssier@inserm.fr.|Université de Montpellier, Montpellier, F-34298, France. catherine.teyssier@inserm.fr.|Institut régional du Cancer de Montpellier, Montpellier, F-34298, France. catherine.teyssier@inserm.fr.
authors: Catherine
authors: C
authors: Teyssier
authors: Université de Montpellier, Montpellier, F-34298, France. c-bret@chu-montpellier.fr.|Département d'Hématologie Biologique, CHU Montpellier, Montpellier, F-34298, France. c-bret@chu-montpellier.fr.|Institut de Génétique Humaine, CNRS UPR 1142, Montpellier, F-34298, France. c-bret@chu-montpellier.fr.
authors: Caroline
authors: C
authors: Bret
authors: Université de Montpellier, Montpellier, F-34298, France. g-cartron@chu-montpellier.fr.|Département d'Hématologie Clinique, CHU Montpellier, Montpellier, F-34298, France. g-cartron@chu-montpellier.fr.|UMR-CNRS 5235, Montpellier, F-34298, France. g-cartron@chu-montpellier.fr.
authors: Guillaume
authors: G
authors: Cartron
authors: Université de Montpellier, Montpellier, F-34298, France. jerome.moreaux@inserm.fr.|Département d'Hématologie Biologique, CHU Montpellier, Montpellier, F-34298, France. jerome.moreaux@inserm.fr.|Institut de Génétique Humaine, CNRS UPR 1142, Montpellier, F-34298, France. jerome.moreaux@inserm.fr.
authors: Jérôme
authors: J
authors: Moreaux
authors: IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, France. vincent.cavailles@inserm.fr.|INSERM, U1194, Montpellier, F-34298, France. vincent.cavailles@inserm.fr.|Université de Montpellier, Montpellier, F-34298, France. vincent.cavailles@inserm.fr.|Institut régional du Cancer de Montpellier, Montpellier, F-34298, France. vincent.cavailles@inserm.fr.
authors: Vincent
authors: V
authors: Cavaillès
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000096:biosynthesis* / Q000235:genetics; D000818:Animals; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000235:genetics*; D009687:Nuclear Proteins / Q000096:biosynthesis* / Q000235:genetics; D000078723:Nuclear Receptor Interacting Protein 1
chemical_list: D048868:Adaptor Proteins, Signal Transducing; C000627127:NRIP1 protein, human; D009687:Nuclear Proteins; D000078723:Nuclear Receptor Interacting Protein 1